CLDX (Celldex Therapeutics) Tariff Resilience Score: 5/10 (As of Jun. 27, 2026)


CLDX Celldex Therapeutics Inc CLDX
57 GF Score
Price $35.23
GF Value $6.88
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Celldex Therapeutics Tariff Resilience Score?

Celldex Therapeutics CLDX +3.43% 57 Tariff Resilience Score is 5 as of Jun. 27, 2026. GuruFocus rates CLDX with a GF Score™ of 57/100 and a GF Value™ of $6.88 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,378 Biotechnology companies, Celldex Therapeutics ranks better than 62.26% on this metric.

Celldex Therapeutics has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Celldex Therapeutics has Celldex Therapeutics, a biotech firm, relies on imported materials for R&D. While tariffs can impact costs, its specialized products and potential pricing power offer some mitigation. Historical impact has been moderate.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Celldex Therapeutics might have Average Resilient.

Celldex Therapeutics  (NAS:CLDX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Celldex Therapeutics Tariff Resilience Score Related Terms

CLDX vs IMNM, ELVN, VERA: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Celldex Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celldex Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's Tariff Resilience Score falls into.


CLDX
57GF Score
Celldex Therapeutics Inc CLDX
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Celldex Therapeutics (CLDX) has a Tariff Resilience Score of 5 as of Jun. 27, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Celldex Therapeutics ranks #520 out of 1378 companies in the Biotechnology industry, placing it in the top 37.7%.
Is Celldex Therapeutics' Tariff Resilience Score too high?
Celldex Therapeutics' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Celldex Therapeutics' value of 5 is 25% above this industry median. Based on the distribution chart, Celldex Therapeutics ranks #520 out of 1378 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Celldex Therapeutics has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celldex Therapeutics' Tariff Resilience Score compare to IMNM and ELVN?
According to the Biotechnology industry distribution chart, Celldex Therapeutics ranks #520 out of 1378 companies for Tariff Resilience Score. This puts Celldex Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Celldex Therapeutics' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,378 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Celldex Therapeutics's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celldex Therapeutics's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celldex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Celldex Therapeutics (CLDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.88, compared to a current price of $35.23 — trading 412.1% above its estimated fair value. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Celldex Therapeutics' overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Celldex Therapeutics (CLDX), the current Tariff Resilience Score is 5 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celldex Therapeutics (CLDX) Overvalued in 2026?

Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued. The current stock price of $35.23 is trading 412.1% above its estimated GF Value™ of $6.88. GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.

Key valuation signals for CLDX:

  • Tariff Resilience Score: 5
  • GF Value™: $6.88 vs. price of $35.23 (412.1% above fair value)
  • GF Score™: 57/100 with 8 warning signs
  • Industry Position: 25% above the Biotechnology median (#520 of 1378)

No single metric tells the full story. See the CLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celldex Therapeutics Business Description

Other Exchanges TCE2:Germany
Address 53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
57GF Score

Get the complete analysis for CLDX

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.23
Price
$6.88
GF Value